Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271028 | 1.00 | HTR3A (0.44) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| Hydrochloric Acid SCHEMBL28701325 | 0.98 | HTR3A (0.43) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| SCHEMBL9182846 | 0.94 | SLC2A1 (0.41) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| Sulfurous Acid SCHEMBL9940685 | 0.91 | SLC18A3 (0.42) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| Sulfurous Acid SCHEMBL9940687 | 0.91 | SLC18A3 (0.42) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| SCHEMBL9311909 | 0.90 | IDO1 (0.45) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| SCHEMBL8517580 | 0.90 | IDO1 (0.45) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| SCHEMBL6853901 | 0.89 | HDAC2 (0.43) | CYP2C9POLBHDAC2 | |
| SCHEMBL10693588 | 0.89 | HTR3A (0.42) | HTR3ASLC2A1SLC18A3DRD2MAPT | |
| SCHEMBL6451314 | 0.83 | HTR3A (0.38) | HTR3ASLC2A1SLC18A3DRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490582-B | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-115490582-A | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| CN-115490582-B | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115490582-B | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115490582-A | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115490582-A | Preparation method of fluorine-containing biphenyl alkene negative monomer liquid crystal compound | 烟台德润液晶材料有限公司 | 2022-12-20 | — | — | CN | disclosed |
| EP-3350164-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017049176-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049176-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080243-A2 | NOVEL PROCESS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080243-A2 | NOVEL PROCESS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| EP-0433836-B1 | Halophenyl substituted dioxanes | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5399689-A | Chlorophenylalkoxyalkyl compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0475254-B1 | Chlorophenyl-alkoxyalkyl-compounds | HOFFMANN LA ROCHE (CH) | 1994-12-28 | — | — | EP | disclosed |
| US-5322638-A | Halophenyl substituted dioxanes | HOFFMANN-LA ROCHE INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0475254-A1 | Chlorophenyl-alkoxyalkyl-compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0433836-A2 | Halophenyl substituted dioxanes | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | HTR3A 102/4885SLC2A1 3756/4885SLC18A3 2540/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | HTR3A 10/4885SLC2A1 1620/4885SLC18A3 2924/4885 |
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | DHPS, VKORC1, DPYD | HTR3A 3301/4885SLC2A1 2286/4885SLC18A3 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.